Technical Analysis for JAGX - Jaguar Animal Health, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Wide Bands | Range Expansion | -9.84% | |
| MACD Bearish Signal Line Cross | Bearish | 1.33% | |
| Wide Bands | Range Expansion | 1.33% | |
| Down 3 Days in a Row | Weakness | 1.33% | |
| Down 4 Days in a Row | Weakness | 1.33% |
| Alert | Time |
|---|---|
| Possible NR7 | 2 days ago |
| Possible Inside Day | 2 days ago |
| 60 Minute Opening Range Breakdown | 2 days ago |
| 60 Minute Opening Range Breakout | 2 days ago |
| Gap Down Partially Closed | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 06/21/2024
Jaguar Animal Health, Inc. Description
Jaguar Animal Health, Inc., a development-stage animal health company, focuses on developing and commercializing gastrointestinal products for companion and production animals. The company's lead prescription drug product candidate includes Canalevia, a canine-specific formulation of Crofelemer for the treatment of CID and general acute watery diarrhea in dogs. It is also developing Crofelemer to treat acute colitis in horses and general acute watery diarrhea in cats; Neonorm, an enteric-coated tablet for scours in preweaned dairy calves, as well as other animal species, such as horses, goats, and sheep; and other product candidates, including Virend and NP-500. The company was founded in 2013 and is headquartered in San Francisco, California. Jaguar Animal Health, Inc. is a subsidiary of Napo Pharmaceuticals, Inc.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Gastrointestinal Animal Health Dog Gastroenterology Prescription Drugs Colitis Drug Products Diarrhea Gastrointestinal Tract Gastrointestinal Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.75 |
| 52 Week Low | 0.0512 |
| Average Volume | 67,244,909 |
| 200-Day Moving Average | 0.23 |
| 50-Day Moving Average | 0.16 |
| 20-Day Moving Average | 0.25 |
| 10-Day Moving Average | 0.29 |
| Average True Range | 0.04 |
| RSI (14) | 55.56 |
| ADX | 58.98 |
| +DI | 35.18 |
| -DI | 10.95 |
| Chandelier Exit (Long, 3 ATRs) | 0.23 |
| Chandelier Exit (Short, 3 ATRs) | 0.27 |
| Upper Bollinger Bands | 0.35 |
| Lower Bollinger Band | 0.14 |
| Percent B (%b) | 0.55 |
| BandWidth | 84.73 |
| MACD Line | 0.04 |
| MACD Signal Line | 0.04 |
| MACD Histogram | -0.0058 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.28 | ||||
| Resistance 3 (R3) | 0.29 | 0.28 | 0.28 | ||
| Resistance 2 (R2) | 0.28 | 0.27 | 0.28 | 0.28 | |
| Resistance 1 (R1) | 0.27 | 0.27 | 0.27 | 0.27 | 0.28 |
| Pivot Point | 0.26 | 0.26 | 0.26 | 0.26 | 0.26 |
| Support 1 (S1) | 0.25 | 0.26 | 0.25 | 0.25 | 0.24 |
| Support 2 (S2) | 0.25 | 0.25 | 0.25 | 0.24 | |
| Support 3 (S3) | 0.24 | 0.25 | 0.24 | ||
| Support 4 (S4) | 0.23 |
